Search Results

You are looking at 61 - 70 of 113 items for :

  • "consolidation therapy" x
  • Refine by Access: All x
Clear All
Full access

Optimize Local Therapy for Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer to Enhance Survival

Joe Y. Chang and Vivek Verma

consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study . J Clin Oncol 2019 ; 37 : 1558 – 1565 . 10.1200/JCO.19

Full access

Identifying Older Patients With Acute Myeloid Leukemia Who May Be Candidates for Reduced-Intensity Hematopoietic Cell Transplantation

Boglarka Gyurkocza and Frederick R. Appelbaum

patient with AML should involve, among other considerations, the assessment of outcomes with standard consolidation therapy. Although long-term remission rates with chemotherapy may approach 40% in some groups of adult patients, the standard chemotherapy

Full access

Evolving Paradigms in the Treatment of Newly Diagnosed Multiple Myeloma

Alessandra Larocca and Antonio Palumbo

Cavo M Tacchetti P Patriarca F . Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed

Full access

Management of Relapsed and Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study . Lancet 2010 ; 376 : 2075 – 2085 . 12 Rajkumar SV Jacobus S Callander NS . Lenalidomide plus

Full access

Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance

Rupali Roy and Leo I. Gordon

grade 3 or 4 infection-related adverse events was significantly higher in patients receiving rituximab maintenance/consolidation therapy than in those undergoing observation (relative risk, 2.9; 95% CI, 1.21–3.27). 43 In long-term follow-up of the EORTC

Full access

Progressive Multifocal Leukoencephalopathy After Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia

Hans C. Lee, Victor Mulanovich, and Yago Nieto

. a complete remission, and then received 2 additional cycles as consolidation therapy. The patient then experienced disease relapse and achieved a second remission after treatment with high-dose cytarabine and vosaroxin followed by decitabine. He then

Full access

Prevention, Diagnosis, and Treatment of Invasive Fungal Infections in Patients with Cancer and Neutropenia

Thomas A. Cumbo and Brahm H. Segal

myeloid leukemia: a Southwest oncology group study (9031) . Blood 1998 ; 91 : 3607 – 3615 . 98 Heil G Hoelzer D Sanz MA . A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation

Full access

Novel Therapies in the Treatment of Multiple Myeloma

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure . J Clin Oncol 2009 ; 27 : 1788 – 1793 . 41 Barlogie B Tricot G

Full access

The Role of Maintenance Therapy in the Treatment of Multiple Myeloma

Ashraf Z. Badros

; 111 : 1805 – 1810 . 16. Spencer A Prince HM Roberts AW . Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

Full access

Lung Cancer Survivorship: Physical, Social, Emotional, and Medical Needs of NSCLC Survivors

Melinda L. Hsu, Matthew Z. Guo, Sarah Olson, Cyd Eaton, Mary Boulanger, Michelle Turner, Mattea E. Miller, Anna Nguyen, Karol Szczepanek, Rahul Shenolikar, and Josephine L. Feliciano

pemetrexed following treatment with pembrolizumab, carboplatin, and pemetrexed) and consolidation therapy (ie, durvalumab following treatment with definitive chemoradiation) were not counted as additional lines of therapy. These distinctions were used to